Emisphere set to benefit as Novo Nordisk pushes oral diabetes pipeline
Novo Nordisk’s focus on developing oral versions of semaglutide and four other diabetes drugs could net drug delivery firm Emisphere over $200m.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs